Europe Antacids Market Size, Share & Industry Trends Analysis Report By Formulation Type (Tablets, Liquids and Others), By Mechanism of Action (Non-systemic and Systemic), By Distribution Channel, By Country and Growth Forecast, 2023 - 2029

The Europe Antacids Market should witness market growth of 3.0% CAGR during the forecast period (2023-2029).

The incidence of mid and early-life deaths is anticipated to drop significantly due to advancements in sanitation, immunization, and other areas. As a result, the senior population uses antacids more frequently. In addition, because of people's reliance on packaged foods as a result of a busy lifestyle, the use of antacids has increased. Fast food, which contains specific preservatives that disrupt digestion and chemicals that cause heartburn, further increases the need for antacids. The demand for acid-regulating medicines is also strengthened by the lack of physical activity, causing obesity as well as chronic gastrointestinal diseases.

The regional antacid market is anticipated to continue to experience rapid growth. This growth is attributed to the region's rising incidence of gastrointestinal diseases and its cutting-edge therapeutic and diagnostic facilities. As a result, antacids are widely available as over-the-counter medications at many brand-name retailers in the region and are in high demand. Another driving force behind the expansion of the European market is the expansion of online pharmacies and the e-commerce industry, which together are helping to meet demand.

Men outweigh women in Italy, where 64.5% of adults over 11 have consumed alcohol at least once, according to a 2015 Ministry of Health study. Among those between 11 and 24 ages, regular alcohol consumption outside of meals was also seen. The market's growth is anticipated to be fueled by the increased prevalence of gastrointestinal conditions such as gastroesophageal reflux and rising alcohol use.

The Germany market dominated the Europe Antacids Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $530.3 Million by 2029. The UK market is anticipated to grow at a CAGR of 2.2% during (2023-2029). Additionally, The France market would exhibit a CAGR of 3.8% during (2023-2029).

Based on Formulation Type, the market is segmented into Tablets, Liquids and Others. Based on Mechanism of Action, the market is segmented into Non-systemic and Systemic. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Alkem Laboratories Ltd., Bayer AG, Cipla Limited, Pfizer, Inc., Prestige Consumer Healthcare, Inc., Reckitt Benckiser Group PLC, WellSpring Pharmaceutical Corporation (Avista Capital Partners), Sanofi S.A. and Sun Pharmaceutical Industries Ltd.

Scope of the Study

By Formulation Type

• Tablets
• Liquids
• Others

By Mechanism of Action

• Non-systemic
• Systemic

By Distribution Channel

• Drug Store & Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Abbott Laboratories
• Alkem Laboratories Ltd.
• Bayer AG
• Cipla Limited
• Pfizer, Inc.
• Prestige Consumer Healthcare, Inc.
• Reckitt Benckiser Group PLC
• WellSpring Pharmaceutical Corporation (Avista Capital Partners)
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd.

Unique Offerings

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free